. 2021 Jan 15;23(4):415–420. doi: 10.4103/aja.aja_72_20

Table 1.

Comparison of clinical characteristics between prostate cancer and nonprostate cancer patients in the study cohort

Group	PCa	Non-PCa	P
Cases, n (%)	236 (44.6)	293 (55.4)
Age (year)
Median (IQR)	70 (66–77)	66 (62–70)
Mean±s.d.	71.26±7.46	66.71±6.72	<0.001^a
PSA value (ng ml⁻¹)
Median (IQR)	15.68 (8.49–36.79)	8.32 (5.82–12.41)
Mean±s.d.	56.51±158.17	10.79±9.75	<0.001^a
Prostate volume (ml)
Median (IQR)	40.13 (30.99–61.77)	45.79 (61.78–82.00)
Mean±s.d.	49.64±28.56	67.09±32.96	<0.001^a
PSAD (ng ml⁻²)
Median (IQR)	0.389 (0.198–0.987)	0.141 (0.098–0.198)
Mean±s.d.	1.209±3.243	0.194±0.233	<0.001^a
TZ-PSAD (ng ml⁻²)
Median (IQR)	0.716 (0.394–1.659)	0.255 (0.149–0.385)
Mean±s.d.	1.853±4.258	0.383±0.523	<0.001^a
PZ-PSAD (ng ml⁻²)
Median (IQR)	0.659 (0.235–2.274)	0.093 (-0.044–0.228)
Mean±s.d.	6.053±31.264	0.208±0.984	<0.001^a
DRE (n)
Normal	112	265
Positive	124	28	<0.001^b
TRUS findings (n)
Normal	87	252
Positive	149	41	<0.001^b
mpMRI findings (n)
Normal	57	215
Positive	179	78	<0.001^b

^aMann-Whitney U test; ^bχ² analysis. PCa: prostate cancer; IQR: interquartile range; s.d.: standard deviation; PSA: prostate-specific antigen; PSAD: prostate-specific antigen density; TZ-PSAD: transition zone prostate-specific antigen density; PZ-PSAD: peripheral zone prostate-specific antigen density; DRE: digital rectal examination; TRUS: transrectal ultrasound; mpMRI: multiparameter magnetic resonance imaging